{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:52:39Z","timestamp":1791049959079,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"DOI":"10.1007\/s11934-026-01368-7","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:06:24Z","timestamp":1791003984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Review of Minimally Invasive Therapies for Men with Overactive Bladder"],"prefix":"10.1007","volume":"27","author":[{"given":"Hayley","family":"Premo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"4","key":"1368_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/nau.25421","volume":"43","author":"A Kapur","year":"2024","unstructured":"Kapur A, Aalami Harandi A, Hartman-Kenzler J, Kim J. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Neurourol Urodyn. 2024;43(4):959\u201366. https:\/\/doi.org\/10.1002\/nau.25421. Epub 20240223.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"1368_CR2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/nau.25538","volume":"43","author":"VW Nitti","year":"2024","unstructured":"Nitti VW, Kohan A, McCammon K, Jenkins B, Ifantides KB, Yushmanova I, et al. Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysis. Neurourol Urodyn. 2024;43(8):1765\u201375. https:\/\/doi.org\/10.1002\/nau.25538. Epub 20240708.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1368_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/nau.25627","volume":"44","author":"H Mohamud","year":"2025","unstructured":"Mohamud H, Sinclair S, Gunamany S, C SB, Zhang CA, Syan R, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025;44(2):319\u201329. https:\/\/doi.org\/10.1002\/nau.25627. Epub 20241119.","journal-title":"Neurourol Urodyn"},{"key":"1368_CR4","doi-asserted-by":"publisher","unstructured":"Wei JT, Dauw CA, Brodsky CN. Lower Urinary Tract Symptoms in Men: A Review. JAMA. 2025;334(9):809\u2009\u2013\u200921. https:\/\/doi.org\/10.1001\/jama.2025.7045. PubMed PMID: 40658396.","DOI":"10.1001\/jama.2025.7045"},{"issue":"8","key":"1368_CR5","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/nau.25532","volume":"43","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. Neurourol Urodyn. 2024;43(8):1742\u201352. https:\/\/doi.org\/10.1002\/nau.25532. Epub 20240715.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"1368_CR6","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/nau.25046","volume":"41","author":"A Kapur","year":"2022","unstructured":"Kapur A, Harandi AA, Cohen T, Ruan H, Dabrowski C, Anderson R, et al. An analysis of factors that influence patient preference of third-line therapy for overactive bladder. Neurourol Urodyn. 2022;41(8):1906\u201313. https:\/\/doi.org\/10.1002\/nau.25046. Epub 20220914.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1368_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/nau.24935","volume":"41","author":"T Soda","year":"2022","unstructured":"Soda T, Koike S, Ikeuchi R, Okada T. Utilization rate and long-term persistence of combination pharmacotherapy with beta3-agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real-world setting. Neurourol Urodyn. 2022;41(5):1165\u201371. https:\/\/doi.org\/10.1002\/nau.24935. Epub 20220414.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1368_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2020.12.032","volume":"79","author":"C De Nunzio","year":"2021","unstructured":"De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol. 2021;79(4):492\u2013504. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.032. Epub 20210102.","journal-title":"Eur Urol"},{"issue":"8","key":"1368_CR9","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/nau.25000","volume":"41","author":"KK Shapiro","year":"2022","unstructured":"Shapiro KK, Brucker BM. Treatment of overactive bladder in men: Is it really different? Neurourol Urodyn. 2022;41(8):1975\u201382. https:\/\/doi.org\/10.1002\/nau.25000. Epub 20220703.","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 5","key":"1368_CR10","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1002\/nau.24076","volume":"38","author":"R Bosch","year":"2019","unstructured":"Bosch R, Abrams P, Averbeck MA, Finazzi Agro E, Gammie A, Marcelissen T, et al. Do functional changes occur in the bladder due to bladder outlet obstruction? - ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S56\u201365. https:\/\/doi.org\/10.1002\/nau.24076. Epub 20190706.","journal-title":"Neurourol Urodyn"},{"key":"1368_CR11","doi-asserted-by":"publisher","unstructured":"Metcalfe PD, Wang J, Jiao H, Huang Y, Hori K, Moore RB et al. Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int. 2010;106(11):1686-94. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09445.x. PubMed PMID: 20590549.","DOI":"10.1111\/j.1464-410X.2010.09445.x"},{"key":"1368_CR12","doi-asserted-by":"crossref","unstructured":"Good DW, Nahas B, Phipps S, Popert R, Stolzenburg J-U, McNeill SAS. Prostate Benign Prostatic Hyperplasia. Blandy\u2019s Urology2019. pp. 531\u2009\u2013\u200961.","DOI":"10.1002\/9781118863343.ch27"},{"issue":"6","key":"1368_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/nau.25435","volume":"43","author":"T Tarcan","year":"2024","unstructured":"Tarcan T, Hashim H, Malde S, Sinha S, Sahai A, Acar O, et al. Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI-RS 2023. Neurourol Urodyn. 2024;43(6):1447\u201357. https:\/\/doi.org\/10.1002\/nau.25435. Epub 20240313.","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"1368_CR14","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(22)00544-7","volume":"23","author":"JM Martin","year":"2022","unstructured":"Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol. 2022;23(12):e534\u201343. 22)00544-7. PubMed PMID: 36455582.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1368_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-024-01238-0","volume":"26","author":"E Neckonoff","year":"2024","unstructured":"Neckonoff E, Anderson CB. Advancements in Understanding and Managing Radiation Cystitis: A Comprehensive Review. Curr Urol Rep. 2024;26(1):1. https:\/\/doi.org\/10.1007\/s11934-024-01238-0. Epub 20240917.","journal-title":"Curr Urol Rep"},{"issue":"4","key":"1368_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.010. Epub 20060104.","journal-title":"Eur Urol"},{"issue":"4","key":"1368_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/toxins8040120","volume":"8","author":"JF Jhang","year":"2016","unstructured":"Jhang JF, Kuo HC, Botulinum Toxin A, Lower Urinary Tract Dysfunction. Pathophysiology and Mechanisms of Action. Toxins (Basel). 2016;8(4):120. Epub 20160421. doi: 10.3390\/toxins8040120. PubMed PMID: 27110822; PubMed Central PMCID: PMC4848644.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"1368_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/nau.24879","volume":"41","author":"JC Truzzi","year":"2022","unstructured":"Truzzi JC, Lapitan MC, Truzzi NC, Iacovelli V, Averbeck MA. Botulinum toxin for treating overactive bladder in men: A systematic review. Neurourol Urodyn. 2022;41(3):710\u201323. https:\/\/doi.org\/10.1002\/nau.24879. Epub 20220203.","journal-title":"Neurourol Urodyn"},{"issue":"2S","key":"1368_CR19","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","volume":"197","author":"VW Nitti","year":"2017","unstructured":"Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017;197(2S):S216\u201323. https:\/\/doi.org\/10.1016\/j.juro.2016.10.109. Epub 20161222.","journal-title":"J Urol"},{"issue":"1","key":"1368_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00345-025-06136-9","volume":"44","author":"S Rahematpura","year":"2026","unstructured":"Rahematpura S, Marantidis J, Wibben A, Romeo H, MacRae K, Kalaga I, et al. Using intravesical botulinum toxin as an adjunct during urologic surgery: a systematic review. World J Urol. 2026;44(1):134. https:\/\/doi.org\/10.1007\/s00345-025-06136-9. Epub 20260129.","journal-title":"World J Urol"},{"issue":"2","key":"1368_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/JU.0000000000000525","volume":"203","author":"L Mateu Arrom","year":"2020","unstructured":"Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L, Gutierrez Ruiz C, Martinez Barea V, Palou Redorta J, et al. Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome. J Urol. 2020;203(2):392\u20137. Epub 20190903. doi: 10.1097\/JU.0000000000000525. PubMed PMID: 31479408.","journal-title":"J Urol"},{"issue":"12","key":"1368_CR22","doi-asserted-by":"publisher","first-page":"CD010098","DOI":"10.1002\/14651858.CD010098.pub4","volume":"12","author":"F Stewart","year":"2016","unstructured":"Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016;12(12):CD010098. https:\/\/doi.org\/10.1002\/14651858.CD010098.pub4. Epub 20161209.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1368_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/nau.24864","volume":"41","author":"A Ghavidel-Sardsahra","year":"2022","unstructured":"Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama IM, Naseri A, Yazdandoost S, Khezerloo T, et al. Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis\/painful bladder syndrome: A systematic review and meta-analysis. Neurourol Urodyn. 2022;41(2):539\u201351. https:\/\/doi.org\/10.1002\/nau.24864. Epub 20220115.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1368_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/nau.25352","volume":"43","author":"M Fourel","year":"2024","unstructured":"Fourel M, Hafez S, Ramdane N, Perrouin-Verbe MA, De Wachter S, Vermersch P, et al. Response to tibial and sacral nerve modulation in overactive bladder: Is there any correlation? Neurourol Urodyn. 2024;43(2):415\u201323. https:\/\/doi.org\/10.1002\/nau.25352. Epub 20231211.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"1368_CR25","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s12325-024-02864-3","volume":"41","author":"UJ Lee","year":"2024","unstructured":"Lee UJ, MacDiarmid S, Matthews CA, Gillespie E, Peters KM. Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices. Adv Ther. 2024;41(7):2635\u201354. https:\/\/doi.org\/10.1007\/s12325-024-02864-3. Epub 20240515.","journal-title":"Adv Ther"},{"key":"1368_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2024.07.046","volume":"194","author":"V Lucente","year":"2024","unstructured":"Lucente V, Giusto L, MacDiarmid S. Two-year Pivotal Study Analysis of the Safety and Efficacy of Implantable Tibial Nerve Stimulation With eCoin(R) for Urgency Urinary Incontinence. Urology. 2024;194:17\u201323. https:\/\/doi.org\/10.1016\/j.urology.2024.07.046. Epub 20240730.","journal-title":"Urology"},{"issue":"2","key":"1368_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/JU.0000000000005062","volume":"216","author":"CL Amundsen","year":"2026","unstructured":"Amundsen CL, Sutherland SE, Heesakkers J, Toozs-Hobson P, Martens F, McCrery RJ, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study. J Urol. 2026;216(2):219\u201329. 0000000000005062. PubMed PMID: 41973947; PubMed Central PMCID: PMC13361951.","journal-title":"J Urol"},{"issue":"6","key":"1368_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/JU.0000000000004958","volume":"215","author":"U Lee","year":"2026","unstructured":"Lee U, Xavier K, Carey J, Pickering A, Harris-Hicks J, Giusto L, et al. Implantable Tibial Neuromodulation Therapy Improves Symptoms of Urge Urinary Incontinence From the TITAN 2 Pivotal Study. J Urol. 2026;215(6):702\u201312. 0000000000004958. PubMed PMID: 41587348; PubMed Central PMCID: PMC13218429.","journal-title":"J Urol"},{"issue":"2","key":"1368_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/JU.0000000000001733","volume":"206","author":"A Rogers","year":"2021","unstructured":"Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin(R) for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial. J Urol. 2021;206(2):399\u2013408. Epub 20210402. doi: 10.1097\/JU.0000000000001733. PubMed PMID: 33797291.","journal-title":"J Urol"},{"issue":"7","key":"1368_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/nau.25477","volume":"43","author":"J Heesakkers","year":"2024","unstructured":"Heesakkers J, Toozs-Hobson P, Sutherland SE, Digesu A, Amundsen CL, McCrery RJ, et al. A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence. Neurourol Urodyn. 2024;43(7):1491\u2013503. https:\/\/doi.org\/10.1002\/nau.25477. Epub 20240418.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1368_CR31","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/nau.24944","volume":"41","author":"K Kapriniotis","year":"2022","unstructured":"Kapriniotis K, Jenks J, Toia B, Pakzad M, Gresty H, Stephens R, et al. Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation? Neurourol Urodyn. 2022;41(5):1172\u20136. https:\/\/doi.org\/10.1002\/nau.24944. Epub 20220428.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1368_CR32","doi-asserted-by":"publisher","first-page":"e4301","DOI":"10.1016\/j.ajog.2023.06.048","volume":"229","author":"JM Warehime","year":"2023","unstructured":"Warehime JM, Gaskins JT, Gupta AS, Hattab EM, Feroz RT, Rothenberger RW, et al. Proximity of percutaneous tibial nerve stimulation needle insertion to surrounding anatomic structures: a cadaveric study. Am J Obstet Gynecol. 2023;229(4):e4301\u20136. https:\/\/doi.org\/10.1016\/j.ajog.2023.06.048. Epub 20230706. PubMed PMID: 37419167.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1368_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.juro.2017.07.010","volume":"199","author":"S Siegel","year":"2018","unstructured":"Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018;199(1):229\u201336. https:\/\/doi.org\/10.1016\/j.juro.2017.07.010. Epub 20170711.","journal-title":"J Urol"},{"key":"1368_CR34","doi-asserted-by":"publisher","unstructured":"Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Toxins (Basel). 2020;12(2). Epub 20200218. https:\/\/doi.org\/10.3390\/toxins12020128. PubMed PMID: 32085542; PubMed Central PMCID: PMC7077313.","DOI":"10.3390\/toxins12020128"},{"issue":"5","key":"1368_CR35","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/nau.23515","volume":"37","author":"HB Goldman","year":"2018","unstructured":"Goldman HB, Lloyd JC, Noblett KL, Carey MP, Castano Botero JC, Gajewski JB, et al. International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn. 2018;37(5):1823\u201348. https:\/\/doi.org\/10.1002\/nau.23515. Epub 20180411.","journal-title":"Neurourol Urodyn"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01368-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:01:48Z","timestamp":1791046908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-026-01368-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01368-7","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Cooper is co-PI of the Male OAB study funded by Boston Scientific.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Disclosure and Human and Animal Rights Statements","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}